CEBINA Bridge Capital
Biotechnology seed capital fund for CEE opportunities.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Seed | |
| Total Funding | 000k | ||
CEBINA Bridge Capital is a regulated venture capital fund that finances seed-stage biotechnology projects sourced from Central and Eastern Europe (CEE). Established in 2021 and registered in Gibraltar, the firm operates as the investment arm of CEBINA (Central European Biotech Incubator and Accelerator), a Vienna-based biotech company. The fund is managed by Danube BioVentures.
The firm's business model centers on identifying and funding promising academic research and early-stage drug discovery projects, transforming them into commercially viable companies. It works in close partnership with CEBINA GmbH, which sources and de-risks opportunities, and Evotec SE, a drug discovery and development partner. This collaboration forms the basis of initiatives like Danube Labs and DanubeNeuro, which aim to establish multiple new biotech companies by investing in therapeutic and neurodegenerative disease-focused research from universities and institutions across the CEE region. Patrick Aisher, an entrepreneur and investor who also leads the family investment company Kinled, heads CEBINA Bridge Capital and serves as a strategic advisor to CEBINA.
CEBINA Bridge Capital's primary fund has a commitment of at least €10 million to support the creation of new biotech ventures. The fund's structure as a regulated Alternative Investment Fund (AIFMD) is designed to offer transparency and investor protection. Investments typically range from pre-seed funding for projects to seed and Series A rounds for newly incorporated companies, often between €1.5 and €4 million. The model provides a direct pipeline from academic innovation in an underserved market to the broader life sciences industry, bridging a critical funding gap in the region.
Keywords: biotech venture capital, seed capital fund, Central and Eastern Europe biotech, life sciences investment, drug discovery financing, academic spin-outs, Danube Labs, Patrick Aisher, CEBINA, therapeutics funding, neurodegeneration investment, early-stage biotech, regulated investment fund, Gibraltar AIFMD, Evotec partnership, life science commercialization, pre-seed funding, biotech accelerator, Vienna biotech ecosystem, university research funding